Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme (Q33387317)

26 July 2017

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme (English)

1 reference

26 July 2017

phase II clinical trial

0 references

0 references

1 reference

12

Gene H Barnett

1 reference

26 July 2017

David M Peereboom

1

1 reference

26 July 2017

Dale R Shepard

2

1 reference

26 July 2017

Manmeet S Ahluwalia

3

1 reference

26 July 2017

Cathy J Brewer

4

1 reference

26 July 2017

Neeraj Agarwal

5

1 reference

26 July 2017

Glen H J Stevens

6

1 reference

26 July 2017

John H Suh

7

1 reference

26 July 2017

Steven A Toms

8

1 reference

26 July 2017

Michael A Vogelbaum

9

1 reference

26 July 2017

Robert J Weil

10

1 reference

26 July 2017

Paul Elson

11

1 reference

26 July 2017

4 December 2009

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

98

1 reference

26 July 2017

1

1 reference

26 July 2017

93-99

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-009-0067-2

26 July 2017

0 references

cites work

EGFR overexpression and radiation response in glioblastoma multiforme

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-0067-2

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-0067-2

Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').

21 January 2018

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

1 reference

12 December 2020

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

1 reference

12 December 2020

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

1 reference

12 December 2020

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme

1 reference

12 December 2020

Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.

1 reference

12 December 2020

EGFR but not PDGFR-beta expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines.

1 reference

12 December 2020

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

1 reference

12 December 2020

Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines

1 reference

12 December 2020

Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma

1 reference

12 December 2020

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

12 December 2020

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme

1 reference

12 December 2020

The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.

1 reference

12 December 2020

Pulmonary fibrosis in a patient treated with erlotinib

1 reference

12 December 2020

The autocrine loop of TGF-alpha/EGFR and brain tumors

1 reference

12 December 2020

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

1 reference

12 December 2020

Phase II trial of gefitinib in recurrent glioblastoma

1 reference

12 December 2020

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme

1 reference

12 December 2020

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

1 reference

12 December 2020

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

1 reference

12 December 2020

Treatment of glioblastoma multiforme: a new standard

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

12 December 2020

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

12 December 2020

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

12 December 2020

p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

1 reference

12 December 2020

Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma.

1 reference

12 December 2020

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

12 December 2020

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.

1 reference

12 December 2020

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

1 reference

12 December 2020

Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

10.1007/S11060-009-0067-2

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference